| Not Yet Recruiting | A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors NCT07460375 | LigaChem Biosciences, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of NCT07534813 | Grit Biotechnology | N/A |
| Not Yet Recruiting | SKB103 for Injection in Advanced Solid Tumors NCT07459998 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors NCT07504445 | Peking University Shenzhen Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | SKB105 for Injection in Advanced Solid Tumors NCT07380386 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. NCT07412665 | Beijing Geekgene Technology Co., LTD | EARLY_Phase 1 |
| Not Yet Recruiting | A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors NCT07509684 | Zhejiang Anglikang Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody NCT07438093 | The First Affiliated Hospital of Xiamen University | N/A |
| Not Yet Recruiting | A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors NCT07482319 | Beijing Geekgene Technology Co., LTD | Phase 1 |
| Not Yet Recruiting | QLS5132 Combination Therapy in Advanced Solid Tumors NCT07453394 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors NCT07524348 | Samsung Bioepis Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer NCT07439094 | Chong Kun Dang Pharmaceutical | Phase 1 / Phase 2 |
| Recruiting | A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. NCT07414316 | Beijing Geekgene Technology Co., LTD | EARLY_Phase 1 |
| Recruiting | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors NCT07360314 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Not Yet Recruiting | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038 | Betta Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | HWS116 Monotherapy in Patients With Advanced Solid Tumors NCT07413328 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Phase 1 |
| Recruiting | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuv NCT07372625 | PMV Pharmaceuticals, Inc | Phase 1 |
| Not Yet Recruiting | A Study of BGM-2121 in Patients With Advanced Solid Tumors NCT07346846 | BioGate Precision Medicine Corp. | Phase 1 |
| Recruiting | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors NCT07387068 | Genmab | Phase 1 |
| Not Yet Recruiting | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor NCT07327294 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors NCT07328217 | Dizal Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in NCT07262619 | Eikon Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors NCT07222969 | Vibrant Sciences Limited | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Ad NCT07349160 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | EARLY_Phase 1 |
| Recruiting | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors NCT07131202 | Suzhou Forlong Biotechnology Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tol NCT07359066 | Shanghai SciBrunch Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation NCT07172919 | Amgen | Phase 2 |
| Not Yet Recruiting | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) NCT07307053 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors NCT07321574 | Shanghai AB PharmaTech Ltd. | Phase 2 |
| Recruiting | Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients NCT07310134 | Nanjing Zenshine Pharmaceuticals | Phase 1 |
| Recruiting | GenSci143 in Participants With Advanced Solid Tumors NCT07252414 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors NCT07266428 | Ottimo Pharma Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | RVU120 Rollover Study NCT06987058 | Ryvu Therapeutics SA | Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Partic NCT07251166 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | BTM-3566 in Advanced Solid Tumors NCT07266285 | Bantam Pharmaceuticals | Phase 1 |
| Recruiting | A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 NCT07446816 | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Not Yet Recruiting | Study of CHO-A04 in Advanced Solid Tumors NCT07049458 | Cho Pharma Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Immune Cell Therapy for Advanced Solid Tumors NCT07260058 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors NCT07275853 | TCRx Therapeutics Co.Ltd | Phase 1 |
| Recruiting | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies NCT07197554 | SEED Therapeutics, Inc. | Phase 1 |
| Recruiting | FL-261 Imaging for Cancer Diagnosis and Staging NCT07510321 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Recruiting | A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants Wit NCT07161414 | AstraZeneca | Phase 1 |
| Recruiting | A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors NCT07253116 | Nanjing Jingao biomidical technology Co. Ltd. | Phase 1 / Phase 2 |
| Recruiting | GenSci139 in Patients With Advanced Solid Tumors NCT07230977 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors NCT07241936 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study NCT07285395 | The Affiliated Hospital of Xuzhou Medical University | Phase 1 |
| Recruiting | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors NCT07208773 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors NCT07208136 | Jemincare | Phase 1 |
| Recruiting | Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastat NCT07215637 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Not Yet Recruiting | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors NCT07207681 | The First Hospital of Jilin University | Phase 1 |
| Not Yet Recruiting | A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors NCT07170787 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumor NCT07077434 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, NCT07231458 | Abalos Therapeutics GmbH | Phase 1 |
| Recruiting | A Study of PHN-012 in Patients With Advanced Solid Tumors NCT07127874 | Pheon Therapeutics | Phase 1 |
| Recruiting | Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid T NCT07186452 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors NCT07169994 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcin NCT07164950 | Sheng Zhang | N/A |
| Recruiting | Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Ad NCT07106814 | Anhui Provincial Hospital | EARLY_Phase 1 |
| Recruiting | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT07156253 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Recruiting | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. NCT07042100 | Sun Pharma Advanced Research Company Limited | Phase 1 |
| Active Not Recruiting | Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Pati NCT07122063 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of AK146D1 for Injection in Advanced Solid Tumors NCT07067567 | Akeso | Phase 1 |
| Recruiting | A Study of HDM2012 in Patients With Advanced Solid Tumor NCT07100249 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) NCT07101549 | changjianhua | Phase 1 |
| Not Yet Recruiting | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harb NCT07060989 | Nutshell Therapeutics (Shanghai) Co., LTD. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors NCT07136558 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in A NCT06998173 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as NCT07148128 | Auricula Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. NCT07356453 | FoRx Therapeutics AG | Phase 1 |
| Recruiting | Study of FID-022 in Participants With Advanced Solid Tumors NCT06694480 | Fulgent Pharma LLC. | Phase 1 |
| Recruiting | A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors NCT06929663 | Akeso | Phase 1 |
| Not Yet Recruiting | A Study of QLS5133 Monotherapy in Advanced Solid Tumors NCT07061639 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors NCT06873789 | Incyte Corporation | Phase 1 / Phase 2 |
| Recruiting | Study of CM518D1 in Patients With Advanced Solid Tumors NCT07019779 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With NCT06819735 | Domain Therapeutics Australia Pty Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Soli NCT07185243 | Hangzhou Converd Co., Ltd. | N/A |
| Recruiting | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combin NCT06719362 | Providence Health & Services | Phase 1 |
| Recruiting | Phase I Study of HBT-708 for Patients With Advanced Solid Tumors NCT06993870 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Recruiting | A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors NCT06990698 | Zhuhai Fapon Biopharma Co., Ltd. | Phase 1 |
| Recruiting | HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors NCT06822998 | HighField Biopharmaceuticals Corporation | EARLY_Phase 1 |
| Recruiting | A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients NCT06990464 | Shanghai Institute Of Biological Products | Phase 1 |
| Recruiting | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors NCT06993844 | Ensem Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors NCT06963502 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of HDM2005 in Patients With Advanced Solid Tumor NCT07004296 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration NCT06973564 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | HW071021 Monotherapy in Patients With Advanced Solid Tumors NCT06882135 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Phase 1 |
| Not Yet Recruiting | Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer NCT06976931 | Jiangsu YaYao Biotechnology Co., Ltd. | EARLY_Phase 1 |
| Recruiting | AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 | Akeso | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors NCT06963398 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) NCT06719973 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Recruiting | Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Adva NCT06840821 | Mainline Biosciences (Shanghai) Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participant NCT06959706 | Tagworks Pharmaceuticals BV | Phase 1 |
| Not Yet Recruiting | Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors NCT06932094 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of QLM2011 in Subjects With Advanced Solid Tumors NCT06925659 | Qilu Pharmaceutical (Hainan) Co., Ltd. | Phase 1 |
| Not Yet Recruiting | First-In-Human Study in Participants With Advanced Solid Tumors NCT06885645 | Chengdu Kanghong Biotech Co., Ltd. | Phase 1 |
| Recruiting | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. NCT06907043 | Eikon Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Trial of HRS-6768 in Patients With Advanced Solid Tumors NCT06925581 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tu NCT06915753 | Tyra Biosciences, Inc | Phase 1 |
| Enrolling By Invitation | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors NCT07053904 | PharmaEssentia | Phase 1 |
| Recruiting | A Study of HS-20122 in Patients With Advanced Solid Tumors NCT06927570 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion NCT06968572 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors NCT06907628 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors NCT06906731 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of PHST001 in Advanced Solid Tumors NCT06840886 | Pheast Therapeutics | Phase 1 |
| Recruiting | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors NCT06895928 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002 NCT06818643 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants Wit NCT06880549 | ModernaTX, Inc. | Phase 1 |
| Recruiting | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tu NCT06799065 | Accent Therapeutics | Phase 1 |
| Not Yet Recruiting | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors NCT06775236 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor NCT06954558 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Not Yet Recruiting | First in Human Study of YB1-X7 Injection NCT06889675 | Shanghai Salvectors Biotechnology LTD. | N/A |
| Recruiting | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569 | Alterome Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System NCT06824792 | NING LI | Phase 4 |
| Not Yet Recruiting | Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors NCT06825455 | Peking University | EARLY_Phase 1 |
| Recruiting | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors NCT06792552 | NextCure, Inc. | Phase 1 |
| Recruiting | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanc NCT06804824 | Vividion Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 | CStone Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 NCT06832982 | Shanghai Pushi Medical Science Co. Ltd | Phase 1 |
| Not Yet Recruiting | Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors NCT06787950 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Phase 1 / Phase 2 |
| Recruiting | SNV4818 in Participants With Advanced Solid Tumors NCT06736704 | Pikavation Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors NCT06703177 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors NCT06697197 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it i NCT06760819 | Bayer | Phase 2 |
| Recruiting | A Study of MGC028 in Participants With Advanced Solid Tumors NCT06723236 | MacroGenics | Phase 1 |
| Recruiting | HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155 | Radiopharm Theranostics, Ltd | EARLY_Phase 1 |
| Recruiting | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors NCT06730750 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors NCT06773091 | Shanghai NK Cell Technology Co., LTD | Phase 1 |
| Recruiting | SKB445 for Injection in Solid Tumors NCT06826040 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease NCT06795815 | Azienda USL Reggio Emilia - IRCCS | N/A |
| Active Not Recruiting | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors NCT06777316 | Cogent Biosciences, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patient NCT06770569 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 |
| Active Not Recruiting | QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations NCT06715124 | Quanta Therapeutics | Phase 1 |
| Recruiting | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients W NCT06801470 | CD (Suzhou) Biopharma Co., Ltd. | Phase 1 |
| Recruiting | A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors NCT07229898 | Henan Genuine Biotech Co., Ltd. | Phase 1 |
| Recruiting | Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the NCT07046650 | Sheng Zhang | Phase 2 |
| Recruiting | A Study of HDM2006 in Patients With Advanced Solid Tumor NCT07377591 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tum NCT06770764 | Trutino Biosciences Inc. | Phase 1 |
| Recruiting | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 | Tubulis GmbH | Phase 1 / Phase 2 |
| Recruiting | A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advan NCT06736327 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Inj NCT06726369 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of SIGX1094R in Patients With Advanced Solid Tumors NCT06739291 | Signet Therapeutics | Phase 1 |
| Recruiting | A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors NCT06643754 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors NCT06686745 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid NCT06704828 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors NCT06618651 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors NCT06610227 | NING LI | EARLY_Phase 1 |
| Not Yet Recruiting | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutatio NCT06594874 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of ZW191 in Participants With Solid Tumors NCT06555744 | Zymeworks BC Inc. | Phase 1 |
| Recruiting | An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the S NCT06238401 | Hangzhou Adcoris Biopharmacy Co., Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Parti NCT06656390 | Shanghai Allink Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors NCT06779851 | Bright Peak Therapeutics Inc | Phase 1 |
| Terminated | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumo NCT06625515 | Accent Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors NCT06544655 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors NCT06605222 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of BG-C477 in Participants With Advanced Solid Tumors NCT06596473 | BeOne Medicines | Phase 1 |
| Not Yet Recruiting | A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy i NCT06598735 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemipl NCT06413680 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase 1 Trial of KH801 NCT06364501 | Beijing Kanghong Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors NCT06520488 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors NCT06532565 | Gilead Sciences | Phase 1 |
| Recruiting | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors NCT07093970 | Lepu Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors NCT06764836 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Recruiting | An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alon NCT06480552 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
| Recruiting | A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations NCT06500676 | Genfleet Therapeutics (Shanghai) Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of SKB518 in Patients With Advanced Solid Tumors NCT06428331 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Trial of SHR-4849 in Advanced Solid Tumors NCT06443489 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | AMT-676 in Patients With Advanced Solid Tumors NCT06400485 | Multitude Therapeutics Inc. | EARLY_Phase 1 |
| Recruiting | Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors NCT06439589 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of YL205 in Patients With Advanced Solid Tumors NCT06459973 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients Wi NCT06474455 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Completed | The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors NCT06381050 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Unknown | AMT-562 in Patients With Selected Advanced Solid Tumors NCT06199908 | Multitude Therapeutics (Australia) Pty Ltd | Phase 1 |
| Recruiting | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors NCT06417554 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Effic NCT06376136 | Bio-Thera Solutions | Phase 1 / Phase 2 |
| Recruiting | AMT-116 in Patients with Solid Tumors NCT06782334 | Multitude Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With NCT06384352 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma NCT06445517 | InSilico Medicine Hong Kong Limited | Phase 1 |
| Recruiting | A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors NCT06394414 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Terminated | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors NCT05949632 | Incyte Corporation | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficac NCT06341114 | Bio-Thera Solutions | Phase 1 / Phase 2 |
| Recruiting | HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors NCT06336707 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors NCT06329206 | Suzhou Genhouse Bio Co., Ltd. | Phase 1 |
| Terminated | Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors NCT06331559 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NCT06131398 | Amgen | Phase 1 |
| Recruiting | A Study for HSK39775 in Participants With Solid Tumors NCT06314373 | Xizang Haisco Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | PAS-004 in Patients With Advanced Solid Tumors NCT06299839 | Pasithea Therapeutics Corp. | Phase 1 |
| Active Not Recruiting | A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors NCT06235983 | Eli Lilly and Company | Phase 1 |
| Completed | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) NCT06242691 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer NCT06239467 | OnKure, Inc. | Phase 1 |
| Withdrawn | A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors NCT06235541 | Genome & Company | Phase 1 |
| Recruiting | AMT-253 in Patients With Advanced Solid Tumours NCT06209580 | Multitude Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in NCT06004245 | Vividion Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies NCT06224855 | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors NCT06208410 | Risen (Suzhou) Pharma Tech Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors NCT06214143 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors NCT06167317 | Gilead Sciences | Phase 1 |
| Terminated | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanc NCT06188208 | Vividion Therapeutics, Inc. | Phase 1 |
| Recruiting | A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors NCT06158477 | Chengdu JOYO pharma Co., Ltd. | Phase 1 |
| Terminated | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C NCT06039384 | Incyte Corporation | Phase 1 |
| Recruiting | An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors NCT06094556 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Not Yet Recruiting | CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency NCT06183736 | Convalife (Shanghai) Co., Ltd. | Phase 2 |
| Recruiting | A Study of JNJ-87890387 for Advanced Solid Tumors NCT06178614 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas NCT06028373 | Antengene Biologics Limited | Phase 1 |
| Recruiting | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments NCT06799637 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus NCT06024174 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Not Yet Recruiting | First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors NCT06134531 | Nanfang Hospital, Southern Medical University | Phase 1 |
| Recruiting | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS NCT06096974 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Recruiting | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Adva NCT05944224 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors NCT05951608 | Akeso | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tum NCT05941507 | LigaChem Biosciences, Inc. | Phase 1 / Phase 2 |
| Unknown | A Study of QL1706H in Patients With Advanced Solid Tumors NCT06047431 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumo NCT06082570 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Unknown | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patie NCT06092268 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors NCT06076291 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 |
| Completed | Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 NCT06012708 | New Cancer Cure-Bio Co.,Ltd. | Phase 1 |
| Recruiting | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541 | Revolution Medicines, Inc. | Phase 1 |
| Not Yet Recruiting | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor NCT06026501 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116 | DualityBio Inc. | Phase 1 / Phase 2 |
| Completed | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximu NCT05774873 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Unknown | A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors NCT05509985 | AskGene Pharma, Inc. | Phase 1 |
| Completed | A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affe NCT05858164 | Bayer | Phase 1 |
| Terminated | HV-101 for Patients With Advanced Solid Tumors NCT05868915 | Hervor Therapeutics | Phase 1 |
| Recruiting | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. NCT05867420 | AskGene Pharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanc NCT05954312 | Vividion Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 | Incyte Corporation | Phase 1 |
| Terminated | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Sol NCT05904496 | BeiGene | Phase 1 |
| Completed | Study of ZGGS15 in Patients With Advanced Solid Tumors NCT05864573 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Active Not Recruiting | A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced NCT06547957 | iTeos Therapeutics | Phase 1 |
| Recruiting | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) NCT05853367 | Merck Sharp & Dohme LLC | Phase 1 |
| Active Not Recruiting | Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors NCT05914376 | Hangzhou Converd Co., Ltd. | Phase 1 |
| Unknown | A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors NCT05942378 | Fudan University | Phase 1 |
| Active Not Recruiting | SKB410 for Injection in Solid Tumors NCT05906537 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Phase 1 |
| Completed | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tum NCT05800964 | Amgen | Phase 1 |
| Active Not Recruiting | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors NCT05888831 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors NCT05881525 | TCRCure Biopharma Ltd. | Phase 1 |
| Unknown | Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors NCT05976906 | Zhejiang University | Phase 1 |
| Recruiting | A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors NCT05830045 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocyt NCT05775406 | Kymera Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors NCT05773820 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignan NCT05880043 | GI Cell, Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors NCT05701709 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Study of KM501 in Patients With Solid Tumors NCT05804864 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors NCT06723964 | AP Biosciences Inc. | Phase 1 |
| Active Not Recruiting | Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors NCT05718219 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monoth NCT05781048 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Terminated | A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant So NCT05824455 | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumo NCT05823285 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Active Not Recruiting | A Trial of SHR-7367 in Subjects With Advanced Solid Tumors NCT05740202 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study of ASP2074 in Adults With Solid Tumors NCT05646797 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Suspended | Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Co NCT05571969 | Allarity Therapeutics | Phase 1 |
| Unknown | Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lympho NCT05564806 | Eucure (Beijing) Biopharma Co., Ltd | Phase 1 |
| Recruiting | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced NCT05541822 | Abion Inc | Phase 2 |
| Terminated | To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Soli NCT05879627 | Bio-Thera Solutions | Phase 1 |
| Recruiting | A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors NCT05564858 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 |
| Withdrawn | A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors NCT05678283 | Bristol-Myers Squibb | Phase 1 |
| Active Not Recruiting | NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated NCT05605496 | Centre Leon Berard | Phase 2 |
| Recruiting | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Part NCT05592626 | Marengo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer NCT05904457 | Asan Medical Center | Phase 2 |
| Recruiting | Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hem NCT07036133 | Acrotech Biopharma Inc. | Phase 1 |
| Recruiting | Phase 1 Trial of KH617 NCT05667194 | Sichuan Honghe Biotechnology Co., Ltd. | Phase 1 |
| Completed | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumor NCT05625412 | Bristol-Myers Squibb | Phase 1 |
| Completed | MEDI5752 in Japanese Patients With Advanced Solid Tumors. NCT05685472 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Int NCT05599984 | AbbVie | Phase 1 |
| Unknown | A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors NCT05609019 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection NCT05620017 | Bio-Thera Solutions | Phase 1 |
| Recruiting | BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors NCT06368960 | InnoBM Pharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combi NCT05614102 | Bayer | Phase 1 |
| Unknown | A Study of ASKG315 in Patients With Advanced Solid Tumors. NCT05554666 | AskGene Pharma, Inc. | Phase 1 |
| Active Not Recruiting | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alon NCT05537740 | Bayer | Phase 1 |
| Terminated | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Canc NCT05543629 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Withdrawn | Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors NCT05469490 | Luke, Jason, MD | Phase 1 |
| Unknown | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors NCT05457517 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 / Phase 2 |
| Unknown | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors NCT05508659 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Completed | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors NCT05494918 | Alphamab (Australia) Co Pty Ltd. | Phase 1 |
| Recruiting | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With NCT05533697 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors NCT05549804 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors NCT05473624 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Terminated | A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors NCT05470933 | Suzhou Junjing BioSciences Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in NCT05487235 | Genentech, Inc. | Phase 1 |
| Unknown | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injectio NCT05214976 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors NCT05287399 | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivol NCT05407675 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Unknown | A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patie NCT05267899 | Zhejiang Haichang Biotech Co., Ltd. | Phase 1 |
| Terminated | A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patient NCT05430555 | T-knife GmbH | Phase 1 / Phase 2 |
| Completed | Study of Relatlimab in Combination With Nivolumab in Chinese Participants NCT05498480 | Bristol-Myers Squibb | Phase 1 |
| Unknown | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors NCT05502393 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Terminated | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors NCT05389462 | ADC Therapeutics S.A. | Phase 1 |
| Terminated | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignan NCT05338346 | Antengene Discovery Limited | Phase 1 |
| Unknown | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity NCT05818917 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tu NCT05394350 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection NCT05378737 | Bio-Thera Solutions | Phase 1 |
| Unknown | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors NCT05688605 | Shanghai Miracogen Inc. | Phase 1 / Phase 2 |
| Unknown | A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers NCT05349409 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Completed | A Study of KL340399 in Patients With Advanced Solid Tumors NCT05387928 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors NCT05393063 | Akeso | Phase 1 |